Zanubrutinib and Venetoclax for Patients With Treatment-Naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma With and Without Del(17p)/ TP53 Mutation: SEQUOIA Arm D Results
Journal of Clinical Oncology · 20.07.2025 · 43 (21) · 2409-2417
DOI: 10.1200/jco-25-00758 ↗Kurz gefasst
Klinische Studie in der Zeitschrift Journal of Clinical Oncology, erschienen am 20.07.2025. Verfasst von Mazyar Shadman und 18 weiteren Autor:innen. Beteiligte Einrichtung: Fred Hutchinson Cancer Center, Seattle, WA. Hauptthemen laut MEDLINE: Antineoplastic Combined Chemotherapy Protocols, Bridged Bicyclo Compounds, Heterocyclic, Leukemia, Lymphocytic, Chronic, B-Cell, Pyrazoles. Die Arbeit wurde bisher 29-mal zitiert (Crossref) und nennt 20 Literaturangaben.
Abstract (Originalsprache)
PURPOSE Several chronic lymphocytic leukemia (CLL) studies have demonstrated promising efficacy with the combination of BCL2 and Bruton tyrosine kinase inhibitors; however, patients with CLL with del(17p) and/or TP53 mutation ( TP53 mut) comprised a small percentage of study populations or were excluded entirely. The purpose of the SEQUOIA Arm D cohort was to evaluate the combination of zanubrutinib + venetoclax in treatment-naïve (TN) patients with CLL/small lymphocytic lymphoma (SLL), in a large population of patients with TP53 -aberrant disease. PATIENTS AND METHODS Arm D is a nonrandomized cohort of patients aged 65 years and older (or 18-64 years with comorbidities). Patients received zanubrutinib from cycle 1 and venetoclax from cycle 4 (ramp-up) to cycle 28, followed by continuous zanubrutinib monotherapy until progressive disease (PD), unacceptable toxicity, or meeting undetectable minimal residual disease (uMRD)-guided stopping criteria. RESULTS Between November 2019 and July 2022, 114 patients were enrolled: 66 (58%) with TP53 -aberrant disease, 47 (41%) without TP53 -aberrant disease, and 1 with missing TP53 results. At a median follow-up of 31.2 months, 85 patients (75%) remained on zanubrutinib monotherapy; 29 patients (25%) discontinued zanubrutinib because of adverse event, uMRD-guided stopping criteria, PD, or other. In the intention-to-treat population, 59% of patients achieved peripheral blood uMRD. The 24-month progression-free survival estimate was 92% (95% CI, 85% to 96%). The most common any-grade treatment-emergent AEs (TEAEs) were COVID-19 (54%), diarrhea (41%), contusion (32%), and nausea (30%). The most common grade ≥3 TEAEs were neutropenia (17%), hypertension (10%), diarrhea (6%), and decreased neutrophil count (6%). CONCLUSION Zanubrutinib + venetoclax demonstrated impressive efficacy and a favorable safety profile in patients with TN CLL/SLL, regardless of the presence of TP53 -aberrant disease.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Fred Hutchinson Cancer Center, Seattle, WA.
- University of Washington, Seattle, WA.
- Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom.
- Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Chicago, IL.
- St Vincent's Hospital Melbourne, Fitzroy, Australia.
- Santa Maria delle Croci Hospital, Ravenna, Italy.
ORCID-Profile: Mazyar Shadman, Talha Munir, Tadeusz Robak, Ian W Flinn, Jennifer R Brown, Paolo Ghia, Constantine S Tam, Wojciech Janowski
Zitieren
APA
Shadman, M., Munir, T., Ma, S., Lasica, M., Tani, M., Robak, T., Flinn, I. W., Brown, J. R., Ghia, P., Ferrant, E., Tam, C. S., Janowski, W., Jurczak, W., Xu, L., Tian, T., Lefebure, M., Agresti, S., Hirata, J., & Tedeschi, A. (2025). Zanubrutinib and Venetoclax for Patients With Treatment-Naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma With and Without Del(17p)/ TP53 Mutation: SEQUOIA Arm D Results. Journal of Clinical Oncology, 43(21), 2409-2417. https://doi.org/10.1200/jco-25-00758
Vancouver
Shadman M, Munir T, Ma S, Lasica M, Tani M, Robak T, et al. Zanubrutinib and Venetoclax for Patients With Treatment-Naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma With and Without Del(17p)/ TP53 Mutation: SEQUOIA Arm D Results. Journal of Clinical Oncology. 2025;43(21):2409-2417. doi:10.1200/jco-25-00758
BibTeX
@article{Shadman2025,
author = {Shadman, Mazyar and Munir, Talha and Ma, Shuo and Lasica, Masa and Tani, Monica and Robak, Tadeusz and Flinn, Ian W and Brown, Jennifer R and Ghia, Paolo and Ferrant, Emmanuelle and Tam, Constantine S and Janowski, Wojciech and Jurczak, Wojciech and Xu, Linlin and Tian, Tian and Lefebure, Marcus and Agresti, Stephanie and Hirata, Jamie and Tedeschi, Alessandra},
title = {Zanubrutinib and Venetoclax for Patients With Treatment-Naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma With and Without Del(17p)/ TP53 Mutation: SEQUOIA Arm D Results},
journal = {Journal of Clinical Oncology},
year = {2025},
volume = {43},
number = {21},
pages = {2409--2417},
doi = {10.1200/jco-25-00758}
}
EUVIMED